ArticleCancer medicine2019

Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.

Xibin Zhuang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.